Cardiovascular Research Technologies (CRT)

Howard Herrmann, MD, University of Pennsylvania, explains details of the SMART Trial 2-year results at CRT 2025, where Evolut performed better hemodynamically than the Sapien 3 TAVR valve in small annuli patients. The study included 87% women.

SMART 2-year TAVR hemodynamic data: Medtronic Evolut is better compared to Edwards Sapien in small annulus patients

Sponsored by Medtronic

Howard Herrmann, MD,  MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.

Thumbnail

TAVR linked to stronger valve performance than SAVR in new 5-year study

TAVR is associated with a significantly lower risk of bioprosthetic valve dysfunction than SAVR, according to new data presented at CRT 2025 and simultaneously published in JACC

Medtronic's Evolut FX TAVR valve, designed with 3 golden markers that improve alignment

Self-expanding TAVR valves still linked to superior durability in patients with small annuli after 2 years

Researchers presented new two-year data from the SMART trial at CRT 2025 in Washington, D.C. Overall, self-expanding TAVR valves continue to show superior valve performance compared to balloon-expandable valves, and clinical outcomes remain comparable.